SCHEMBL892029

SCHEMBL892029

O=C(NCCc1c[nH]c2ccc(Cl)cc12)C(=O)NC(CO)C1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.61
MMP8 P22894 1/20 0.61
MMP14 P50281 1/20 0.61
MTNR1A P48039 1/20 0.55
MTNR1B P49286 1/20 0.55
SNCA P37840 9/20 0.55
TSHR P16473 1/20 0.53
P2RX7 Q99572 2/20 0.48
GFER P55789 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HPGD P15428 1/20 0.47
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18601568 1.00 MMP9 (0.61) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL18207221 1.00 MMP9 (0.61) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL892344 0.80 MMP9 (0.65) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL18040138 0.76 MMP9 (0.62) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL18040137 0.76 MMP9 (0.62) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL892509 0.76 MMP9 (0.62) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL892461 0.76 MMP9 (0.79) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL892597 0.76 MMP9 (0.79) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL18642879 0.76 MMP9 (0.52) MMP9MMP8MMP14MTNR1AMTNR1B
SCHEMBL31293096 0.74 MTNR1A (0.67) MMP9MMP8MMP14MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN MMP9 4393/4885MMP8 4446/4885MMP14 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.